HALIFAX, July 30 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today an updated listing of the Company's Board of Directors. The MedMira Board of Directors is comprised of the following individuals:
Stephen Sham, Chairman of the Board
Hermes Chan, Director, President & CEO, MedMira Inc.
David Harris, Director
Dr. Michael Katz, Director
Dr. James Smith, Director, VP of Corporate Affairs, MedMira Inc.
Dr. Shou-Ching Tang, Director
Full profiles on each of the Company's directors can be found on MedMira's website at www.medmira.com.
About MedMira
MedMira is a leading developer, manufacturer, and marketer of advanced rapid diagnostics. Built on the Company's patented rapid flow-through technology platform, MedMira's single and multiple rapid tests provide hospitals, labs, clinics and individuals around the world with reliable, diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests, which are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets, have achieved regulatory approvals in Canada, the United States, China, Russia, India, and the European Union. MedMira is an approved supplier to US Agency for International Development (USAID) and the Pan American Health Organization (PAHO).
In 2006, MedMira launched the Maple Biosciences division to develop and commercialize diagnostic instruments based on biosensor technology platforms. For more information visit www.maplebio.com.
MedMira's corporate offices, R&D, and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
%SEDAR: 00013053E